Skip to main content
. 2020 Oct 12;6(1):101–109. doi: 10.1016/j.ekir.2020.09.046

Figure 2.

Figure 2

Individual evolution of the levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), albumin, and proteinuria along follow-up. 0, At the start of treatment with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, 1–6 monthly values after starting treatment with PCSK9 inhibitors; basal, before the diagnosis of nephrotic syndrome; dx, at diagnosis of nephrotic syndrome, pre1 and pre2 during follow-up after the diagnosis of nephrotic syndrome and before starting treatment with PCSK9 inhibitors; LFU: last follow-up.